[go: up one dir, main page]

ZA961427B - Pharmaceuticals and assays using enzyme subunits - Google Patents

Pharmaceuticals and assays using enzyme subunits

Info

Publication number
ZA961427B
ZA961427B ZA961427A ZA961427A ZA961427B ZA 961427 B ZA961427 B ZA 961427B ZA 961427 A ZA961427 A ZA 961427A ZA 961427 A ZA961427 A ZA 961427A ZA 961427 B ZA961427 B ZA 961427B
Authority
ZA
South Africa
Prior art keywords
agent
pharmaceuticals
assays
constituted
components
Prior art date
Application number
ZA961427A
Other languages
English (en)
Inventor
Richard William Titball
Francis Joseph Carr
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Secr Defence filed Critical Secr Defence
Publication of ZA961427B publication Critical patent/ZA961427B/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/81Packaged device or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • Y10S977/907Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA961427A 1995-02-22 1996-02-22 Pharmaceuticals and assays using enzyme subunits ZA961427B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9503486.4A GB9503486D0 (en) 1995-02-22 1995-02-22 Pharmaceuticals and assays using enzyme subunits

Publications (1)

Publication Number Publication Date
ZA961427B true ZA961427B (en) 1996-08-07

Family

ID=10770034

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961427A ZA961427B (en) 1995-02-22 1996-02-22 Pharmaceuticals and assays using enzyme subunits

Country Status (15)

Country Link
US (2) US6472365B1 (xx)
EP (1) EP0810880B1 (xx)
JP (1) JPH11500136A (xx)
KR (1) KR19980702499A (xx)
CN (1) CN1188704C (xx)
AT (1) ATE224204T1 (xx)
AU (1) AU714396B2 (xx)
CA (1) CA2213566A1 (xx)
DE (1) DE69623755T2 (xx)
DK (1) DK0810880T3 (xx)
ES (1) ES2182962T3 (xx)
GB (1) GB9503486D0 (xx)
PT (1) PT810880E (xx)
WO (1) WO1996025952A1 (xx)
ZA (1) ZA961427B (xx)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4463090A (en) * 1981-09-30 1984-07-31 Harris Curtis C Cascade amplification enzyme immunoassay
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
US4874710A (en) * 1986-02-20 1989-10-17 Becton Dickinson And Company Assay and product in which binder and liposomes are supported on a solid support
EP0301333A3 (en) 1987-07-29 1992-07-01 Abbott Laboratories Liposome based homogeneous immunoassay for diagnostic tests
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
JPH04200632A (ja) 1990-11-29 1992-07-21 Toyo Ink Mfg Co Ltd リポソームの破壊方法
JPH0556797A (ja) 1991-08-31 1993-03-09 Toyo Ink Mfg Co Ltd リポソーム破壊物質の検出方法
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
DE69407292T2 (de) * 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen

Also Published As

Publication number Publication date
DE69623755D1 (de) 2002-10-24
US20020035084A1 (en) 2002-03-21
WO1996025952A1 (en) 1996-08-29
ES2182962T3 (es) 2003-03-16
CA2213566A1 (en) 1996-08-29
JPH11500136A (ja) 1999-01-06
AU4725996A (en) 1996-09-11
EP0810880B1 (en) 2002-09-18
EP0810880A1 (en) 1997-12-10
PT810880E (pt) 2003-02-28
US6472365B1 (en) 2002-10-29
ATE224204T1 (de) 2002-10-15
GB9503486D0 (en) 1995-04-12
AU714396B2 (en) 2000-01-06
DK0810880T3 (da) 2003-01-06
DE69623755T2 (de) 2003-06-05
US6974699B2 (en) 2005-12-13
KR19980702499A (ko) 1998-07-15
CN1188704C (zh) 2005-02-09
CN1182372A (zh) 1998-05-20

Similar Documents

Publication Publication Date Title
Bade et al. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates
Ciruela et al. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors
Ohashi et al. ADP-ribosylation of a Mr 21,000 membrane protein by type D botulinum toxin.
Rohrbach et al. Purification and substrate specificity of bovine angiotensin-converting enzyme.
Tagaya et al. A new affinity labeling reagent for the active site of glycogen synthase. Uridine diphosphopyridoxal.
Nakanishi et al. Direct evidence for interaction between COOH-terminal regions of cytochrome b558 subunits and cytosolic 47-kDa protein during activation of an O (2-)-generating system in neutrophils.
Mary et al. Posttranslational Modifications in the C-terminal Tail of Axonemal Tubulin from Sea Urchin Sperm (∗)
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
WEIR et al. Destruction of endogenous peroxidase activity in order to locate cellular antigens by peroxidase-labeled antibodies
Ozols Isolation and characterization of a 60-kilodalton glycoprotein esterase from liver microsomal membranes.
EP1111385A3 (en) Enzyme-protein complex
Keil et al. Biogenesis of the mitochondrial receptor complex. Two receptors are required for binding of MOM38 to the outer membrane surface.
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
Berleth et al. Inhibition of ubiquitin-protein ligase (E3) by mono-and bifunctional phenylarsenoxides. Evidence for essential vicinal thiols and a proximal nucleophile.
Paul et al. Site specificity of a catalytic vasoactive intestinal peptide antibody. An inhibitory vasoactive intestinal peptide subsequence distant from the scissile peptide bond.
GB9503486D0 (en) Pharmaceuticals and assays using enzyme subunits
Rippa et al. Evidence for multiple pairs of vicinal thiols in some proteins.
Ponce-Soto et al. Structural and biological characterization of two crotamine isoforms IV-2 and IV-3 isolated from the Crotalus durissus cumanensis venom
Ieki et al. Regulated bioanalysis of antibody-drug conjugates using LC-MS
Shime et al. Association of Pasteurella multocida toxin with vimentin
Lugnier et al. Action of ricin from Ricinus communis L. seeds on eukaryote ribosomal proteins
Primiano et al. Enhanced expression, purification, and characterization of a novel class α glutathione S-transferase isozyme appearing in rabbit hepatic cytosol following treatment with 4-picoline
Barrieux et al. Nonidentity of the 48,000-dalton protein of mRNA-protein particles and the beta subunit of eukaryotic initiation factor 2.
Choumet et al. Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of Bungarus fasciatus by genetic recombination
Zibirre et al. Detection and localization of a cytoplasmic domain on the beta-subunit of Na+, K+-ATPase. A monoclonal antibody study.